119-HR-7837 Journalist Public Summary
119 · HR 7837 Most Favored Patient Act of 2026
A House bill would require Medicare and Medicaid’s innovation center to run a five‑year test starting January 1, 2029, that ties certain drug prices paid for Medicare and Medicaid patients to the “most‑favored‑nation” rate (defined here as the second‑lowest price among eight peer countries), with an off‑ramp for manufacturers that sign agreements—including a pledge to increase U.S. manufacturing—before 2029. (govinfo.gov)
Headline Summary
A new House bill would make Medicare’s innovation arm test international reference pricing for drugs—aiming to give eligible U.S. patients access to prices comparable to other wealthy countries—starting in 2029. (govinfo.gov)
What It Does
The Most Favored Patient Act of 2026 orders the Center for Medicare and Medicaid Innovation (CMMI) to run a five‑year model beginning January 1, 2029. Drugmakers that don’t sign a qualifying agreement must offer “most‑favored‑nation” prices to Medicare and Medicaid patients and providers. Here, MFN means the second‑lowest net price available in Canada, Denmark, France, Germany, Italy, Japan, Switzerland, or the United Kingdom, adjusted for purchasing power. The bill also lets the Secretary pause requirements for a specific drug until April 1, 2029, if a deal is likely, and it defines a “covered agreement” to include a commitment to increase U.S. manufacturing. (govinfo.gov)
Why It Matters
Supporters say pegging U.S. prices to peer nations could cut what Medicare and Medicaid pay for expensive drugs, putting downward pressure on patient out‑of‑pocket costs. Past federal proposals to use international reference prices at CMMI underscore the idea’s budget and patient‑cost focus. (cms.gov)
Who’s For It
- Sponsor: Rep. Dan Meuser (R‑PA) says the bill would lower prescription costs and builds on the Trump administration’s drug‑pricing push; his office highlights industry interest and potential savings. (meuser.house.gov)
- Backers of international reference pricing in prior CMS/CMMI proposals argue it can restrain Medicare drug spending growth. (cms.gov)
Who’s Against It
- Free‑market and taxpayer groups (e.g., Council for Citizens Against Government Waste) call MFN a form of foreign price control that could reduce access and slow innovation. (ccagw.org)
- Policy analysts at the American Action Forum warn MFN could undermine Medicare Part D’s market design and push distribution changes that disrupt coverage. (americanactionforum.org)
- Business groups such as the U.S. Chamber of Commerce argue MFN would import other countries’ access delays and hurt biopharma investment. (uschamber.com)
What’s Next
As of March 5, 2026, the bill was introduced and referred to the House Committees on Energy and Commerce and on Ways and Means. It has not yet had a hearing or vote. (legiscan.com)
Discussion